Skip to main content

Table 6 Cox proportional hazard models for time to progression in individuals with NC or MCI

From: Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts

  

Model 1: no covariates

 

Model 2: + sex, age, education

 

Model 3: model 2 + amyloid status

 

Model 4: model 3 + diagnosis

 

Model 5: model 4+ APOE-e4 carriership

 
  

HR (95%CI)

p

HR (95%CI) sex, age, edu

p

HR (95%CI) sex, age, edu, abeta

p

HR (95%CI) sex, age, edu, abeta, diagnosis

p

HR (95%CI) sex, age, edu, abeta, diagnosis, APOE-e4

p

T-tau subgroups

 Subgroup 1

All

Reference

         

 Subgroup 2

ADC: Innotest

6.3 (4.3, 9.2)

5.79E−21

6 (3.9, 9.2)

1.32E−16

3.4 (2.2, 5.3)

5.96E−08

3.4 (2.1, 5.3)

1.08E−07

3.3 (2.1, 5.3)

4.31E−07

ADNI: Luminex

2.1 (1.4, 3)

8.76E−05

2 (1.4, 3)

1.58E−04

1.7 (1.2, 2.5)

5.84E−03

1.6 (1.1, 2.4)

1.24E−02

1.5 (1, 2.2)

2.98E−02

ADNI: Elecsys

1.9 (1.3, 2.8)

9.27E−04

1.8 (1.2, 2.7)

2.44E−03

1.8 (1.2, 2.7)

2.56E−03

1.8 (1.2, 2.6)

3.71E−03

1.7 (1.1, 2.5)

9.74E−03

 Subgroup 3

ADC: Innotest

14.6 (9.8, 21.8)

6.14E−39

13.2 (8.3, 20.8)

3.31E−28

6.2 (3.8, 10)

1.96E−13

6.0 (3.7, 9.8)

6.96E−13

6.1 (3.7, 10.1)

1.86E−12

ADNI: Luminex

5.2 (3.6, 7.6)

1.31E−18

4.9 (3.4, 7.2)

3.53E−17

2.8 (1.9, 4.1)

2.86E−07

2.6 (1.8, 3.9)

1.57E−06

2.4 (1.6, 3.6)

1.06E−05

ADNI: Elecsys

4.4 (3, 6.4)

6.15E−14

4 (2.7, 5.9)

2.05E−12

3.1 (2.1, 4.5)

1.88E−08

2.8 (1.9, 4.2)

1.91E−07

2.7 (1.8, 4)

1.60E−06

 Subgroup 4

ADC: Innotest

21.3 (7.5, 60.6)

9.81E−09

15 (4.4, 50.9)

1.43E−05

6.5 (1.9, 22.3)

2.93E−03

6.6 (1.9, 22.7)

2.70E−03

6.4 (1.9, 22.2)

3.30E−03

ADNI: Luminex

6.7 (4.2, 10.7)

1.01E−15

6.6 (4.1, 10.6)

3.89E−15

3.4 (2.1, 5.6)

8.31E−07

2.8 (1.7, 4.5)

6.50E−05

2.6 (1.5, 4.2)

2.63E−04

ADNI: Elecsys

7.1 (4.3, 11.7)

2.96E−14

7.2 (4.3, 12)

2.37E−14

4.6 (2.7, 7.7)

6.71E−09

3.9 (2.3, 6.6)

2.99E−07

3.5 (2.1, 6.1)

3.59E−06

P-tau subgroups

 Subgroup 1

All

Reference

         

 Subgroup 2

ADC: Innotest

4.4 (3.1, 6.2)

4.13E−17

3.9 (2.7, 5.7)

2.35E−12

2.1 (1.4, 3.2)

1.71E−04

2.1 (1.4, 3.1)

2.28E−04

2.1 (1.4, 3.2)

4.88E−04

ADNI: Luminex

2.2 (1.5, 3)

7.78E−06

2.1 (1.5, 3)

1.38E−05

1.5 (1.0, 2.1)

3.30E−02

1.4 (1.0, 2.0)

5.85E−02

1.4 (1, 2)

7.19E−02

ADNI: Elecsys

2.6 (1.9, 3.6)

9.65E−10

2.6 (1.9, 3.5)

3.83E−09

2.2 (1.6, 3.0)

1.73E−06

2.0 (1.5, 2.8)

1.22E−05

2 (1.4, 2.7)

4.34E−05

 Subgroup 3

ADC: Innotest

10.2 (7, 14.8)

1.48E−33

8.4 (5.6, 12.8)

1.10E−23

3.7 (2.4, 5.8)

6.58E−09

3.6 (2.3, 5.6)

2.03E−08

3.5 (2.2, 5.6)

1.02E−07

ADNI: Luminex

4.4 (3.1, 6.3)

1.81E−16

4.3 (3.0, 6.2)

4.37E−16

2.3 (1.6, 3.3)

1.80E−05

2.2 (1.5, 3.2)

7.21E−05

2 (1.4, 3)

2.88E−04

ADNI: Elecsys

5.0 (3.6, 7.1)

7.09E−20

4.7 (3.3, 6.7)

4.35E−18

3.0 (2.1, 4.3)

4.19E−09

2.7 (1.9, 3.9)

1.32E−07

2.6 (1.8, 3.7)

8.22E−07

 Subgroup 4

ADC: Innotest

9.5 (3.4, 26.5)

1.69E−05

4.6 (1.4, 15.5)

1.28E−02

2.1 (0.6, 7.2)

2.19E−01

2.1 (0.6, 7.1)

2.29E−01

4 (1.2, 13.8)

2.72E−02

ADNI: Luminex

5.0 (2.4, 10.6)

2.83E−05

5.8 (2.7, 12.4)

5.32E−06

2.5 (1.2, 5.5)

1.76E−02

2.3 (1.0, 4.9)

3.81E−02

2.1 (0.9, 4.5)

6.85E−02

ADNI: Elecsys

7.7 (4.7, 12.6)

3.47E−16

8.2 (4.9, 13.4)

1.24E−16

4.7 (2.8, 7.7)

3.52E−09

3.9 (2.3, 6.6)

2.51E−07

3.6 (2.1, 6.1)

2.11E−06

Amyloid status

 Amyloid abnormal

ADC: Innotest (< 813 pg/ml)1

10.8 (7.3, 15.9)

8.71E−33

8.9 (5.9, 13.4)

6.65E−25

n.t.

 

7.8 (5.0, 12.0)

1.88E−20

7.2 (4.5, 11.5)

5.27E−17

ADNI: Luminex (< 192 pg/ml)2

5.2 (3.8, 7.0)

2.29E−25

5.0 (3.6, 6.8)

4.91E−24

n.t.

 

4.4 (3.2, 6.0)

1.79E−20

3.8 (2.7, 5.3)

4.16E−15

ADNI: Elecsys (< 880 pg/ml)3

4.2 (3.2, 5.5)

1.60E−26

4.1 (3.1, 5.3)

8.27E−25

n.t.

 

3.5 (2.7, 4.6)

1.30E−19

3 (2.2, 4)

2.51E−13

Continuous predictors

 Continuous ab1-42 (z score; HR per SD)

ADC: Innotest

0.3 (0.2, 0.4)

3.31E−36

0.3 (0.3, 0.4)

8.16E−27

0.6 (0.4, 0.8)

2.84E−03

0.6 (0.4,0.9)

4.17E−03

0.6 (0.4, 0.8)

4.75E−03

ADNI: Luminex

0.5 (0.4, 0.5)

1.71E−30

0.5 (0.4, 0.5)

6.62E−23

0.6 (0.5, 0.8)

7.12E−05

0.7 (0.5, 0.9)

2.19E−03

0.7 (0.6, 0.9)

1.79E−02

ADNI: Elecsys

0.4 (0.3, 0.5)

2.24E−23

0.4 (0.3, 0.5)

7.05E−22

0.6 (0.4, 0.8)

1.14E−04

0.6 (0.5,0.8)

1.56E−04

0.6 (0.5, 0.8)

5.41E−04

 Continuous t-tau (z score; HR per SD)

ADC: Innotest

1.6 (1.5, 1.7)

7.67E−58

1.9 (1.7, 2.1)

3.60E−32

1.5 (1.3, 1.7)

2.42E−11

1.5 (1.3, 1.7)

4.57E−11

1.6 (1.4, 1.8)

3.46E−11

ADNI: Luminex

1.7 (1.6, 1.9)

7.95E−32

1.7 (1.6, 1.9)

5.61E−31

1.4 (1.3, 1.6)

1.80E−11

1.4 (1.2, 1.5)

1.15E−08

1.3 (1.2, 1.5)

1.69E−07

ADNI: Elecsys

1.6 (1.5, 1.8)

8.36E−27

1.7 (1.5, 1.8)

1.39E−25

1.4 (1.3, 1.6)

2.41E−13

1.4 (1.3, 1.5)

1.51E−10

1.4 (1.2, 1.5)

4.90E−09

 Continuous p-tau (z score; HR per SD)

ADC: Innotest

1.8 (1.7, 2.0)

2.92E−42

1.7 (1.5, 1.9)

3.31E−22

1.4 (1.2, 1.6)

1.11E−07

1.4 (1.2, 1.6)

3.56E−07

1.5 (1.3, 1.7)

3.03E−08

ADNI: Luminex

1.5 (1.4, 1.6)

5.58E−24

1.6 (1.4, 1.7)

1.75E−25

1.3 (1.2, 1.5)

1.67E−08

1.3 (1.2, 1.4)

2.46E−07

1.3 (1.1, 1.4)

4.28E−06

ADNI: Elecsys

1.7 (1.5, 1.8)

3.36E−31

1.7 (1.5, 1.9)

1.06E−29

1.5 (1.3, 1.6)

1.72E−13

1.4 (1.3, 1.5)

9.62E−11

1.4 (1.2, 1.5)

3.05E−09

  1. N.t. not tested
  2. 1Source: Tijms BM et al., Clinical Chemistry. 2018;64(3):576–585
  3. 2Source: [21]
  4. 3Source: Hansson O et al., Alzheimer’s & Dementia. 2018;14(11):1470–1481